The Chinese Herb Extract Wenxin Keli: A Promising Agent for the Management of Atrial Fibrillation.
Yang Liu,Zhiwei Zhang,Yajuan Yang,Nixiao Zhang,Guangping Li,Tong Liu
DOI: https://doi.org/10.1016/j.ijcard.2015.10.211
IF: 4.039
2016-01-01
International Journal of Cardiology
Abstract:Atrial fibrillation (AF) is a common cardiac rhythm disturbance, rising in prevalence with age. An estimated 2.5 million people in North America and 4.5 million in Europe are attacked by AF, which is responsible for largish morbidity and mortality. Although radiofrequency and cryo-ablation therapy have been widely used in the management of AF, antiarrhythmic drugs remain as the first-line therapy for rhythm control of AF [ 1 Chugh S.S. Havmoeller R. Narayanan K. Singh D. Rienstra M. Benjamin E.J. et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. Feb 25 2014; 129: 837-847 Crossref PubMed Scopus (2863) Google Scholar , 2 Ferrari R. Bertini M. Blomstrom-Lundqvist C. Dobrev D. Kirchhof P. Pappone C. et al. An update on atrial fibrillation in 2014: from pathophysiology to treatment. Int. J. Cardiol. Oct 18 2015; 203: 22-29 Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar ]. Wenxin Keli (WXKL) is a traditional Chinese herb extract with anti-arrhythmic effects, which is composed of five components: Nardostachys chinensis Batal extract (NcBe), Codonopsis, Notoginseng, amber, and Rhizoma Polygonati. In clinical practice, WXKL can markedly improve the patients' symptoms including palpitations, chest tightness, fatigue, insomnia, and others and that it have significant effects on ameliorating different types of arrhythmias including atrial and ventricular premature contractions and sinus tachycardia [ 3 Hua W. Gao R.L. Zhao B.C. Wang J. Chen X.H. Cai C. et al. The efficacy and safety of Wenxin Keli in patients with frequent premature ventricular contractions: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Chin. Med. J. 5th Oct 2015; 128: 2557-2564 Crossref PubMed Scopus (21) Google Scholar , 4 Brenyo A. Aktas M.K. Review of complementary and alternative medical treatment of arrhythmias. Am. J. Cardiol. Mar 1 2014; 113: 897-903 Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar ]. Previous study [ [5] Xue X. Guo D. Sun H. Wang D. Li J. Liu T. et al. Wenxin Keli suppresses ventricular triggered arrhythmias via selective inhibition of late sodium current. Pacing Clin. Electrophysiol. Jun 2013; 36: 732-740 Crossref PubMed Scopus (26) Google Scholar ] has shown that Wenxin Keli suppressed early after depolarizations (EADs), delayed after depolarizations (DADs), and triggered ventricular arrhythmias through selective inhibition of late INa that is proved to contribute to arrhythmogenesis. Also, Xing et al. [ [6] Xing Y. Gao Y. Chen J. Zhu H. Wu A. Yang Q. et al. Wenxin-Keli regulates the calcium/calmodulin-dependent protein kinase II signal transduction pathway and inhibits cardiac arrhythmia in rats with myocardial infarction. Evid. Based Complement. Alternat. Med. 2013; 2013: 464508 Crossref PubMed Scopus (29) Google Scholar ] demonstrated that WXKL prevented heart failure and cardiac arrhythmias through a potential mechanism involving the regulation of the CaMKII signal transduction pathway. WXKL has been found to inhibit the Ca2+ transient amplitude in ISO-stimulated cardiac myocytes, WXKL increased both the sarcoplasmic reticulum (SR) Ca2+ content and the calcium transient amplitude in isolated cardiac myocytes from rats with myocardial infarction, while also significantly decreased the incidence of EADs and DADs in these isolated cardiac myocytes. In addition, WXKL markedly reduced the incidence of cardiac arrhythmias in vivo rat myocardial infarction model.